Authorizing Medical Cannabis for Veterans: A Clinical Evidence Summary
Last Updated: February 2026 | Reading Time: 5 minutes
Canadian veterans are using medical cannabis at documented rates, often without clinical guidance and frequently sourcing information from peers rather than healthcare providers. This article summarizes the peer-reviewed evidence base for clinicians considering medical cannabis authorization for veteran patients — what the research shows, where findings are equivocal, and what the medicinal versus recreational distinction means in practice.
Prevalence: What Clinicians Are Already Seeing
A 2023 cross-sectional study by St. Cyr, Nazarov, Le et al., published in BMC Psychiatry (23: 836), examined 415 Canadian Armed Forces members and veterans attending the St. Joseph’s Operational Stress Injury Clinic in London, Ontario between 2018 and 2020. The finding is direct: 45.1% of this clinical sample reported current cannabis use for medical or recreational purposes, in the absence of clinical practice guidelines addressing it.
This is the baseline reality for clinicians working with this population. Veterans are not waiting for formal guidance — they are already using cannabis. A 2023 qualitative study by Storey, Keeler-Villa, Harris, Anthonypillai, Tippin, Parihar & Rash (Canadian Journal of Pain, 7(1): 2232838) documented that most of the 12 Canadian veterans with chronic pain they interviewed had initiated cannabis independently to manage symptoms of preexisting conditions, before or outside of formal clinical guidance. The decision to authorize or decline authorization therefore shapes the safety and consistency of access to cannabis that is already occurring — not whether it occurs.
The Medicinal Versus Recreational Distinction
The most clinically important signal in the current literature is the difference in outcomes between authorized medicinal use and recreational use. Sheehy, Storey, Rash, Tippin, Parihar & Harris (2025, Journal of Veterans Studies, 11(1)) note in their background that prior studies found a recurring pattern: recreational cannabis use was associated with worsening PTSD-related outcomes in some studies, while medicinal cannabis accessed through authorized channels was associated with improved outcomes. Sheehy et al.’s own cross-sectional data did not reach statistical significance for this association, which the authors attribute partly to the treatment-seeking nature of their sample and design limitations. The prior literature they cite remains clinically relevant.
The practical implication for authorization decisions is straightforward. Veterans who are already using cannabis recreationally are accessing an unregulated supply with unknown concentrations, variable product consistency, and no clinical oversight. Authorization moves their access into a regulated, documented, clinically monitored context — it does not introduce cannabis use that was not already occurring.
Pain and Sleep: Where the Evidence Is Strongest
Chronic pain is the primary condition driving medical cannabis authorization in Canada. A 2019 survey of 2,032 authorized patients in Canada’s federal medical cannabis program by Lucas, Baron & Jikomes (Harm Reduction Journal, 16(1): 9) found that pain and mental health conditions broadly defined — chronic pain, arthritis, headache, mental health conditions, PTSD, and insomnia — accounted for 83.7% of respondents. The same survey found that 69.1% of authorized patients reported substituting cannabis for prescription drugs, a substitution pattern relevant for patients on opioid therapy, benzodiazepines, or sleep medications.
For sleep specifically, a 2023 retrospective study by Nacasch, Avni & Toren (Frontiers in Psychiatry, 13: 1014630) followed 14 treatment-resistant combat veterans and found significant improvements in sleep quality, subjective sleep quality, and sleep duration (p<0.01), and in total PTSD severity and the intrusiveness, avoidance, and alertness subdomains (p<0.05) following medical cannabis use. Nightmare frequency did not significantly improve (p=0.27). Sleep improvement is the most consistent finding across the veteran literature. The treatment-resistant designation is clinically relevant: these were patients for whom prior pharmacological and psychotherapy interventions had not produced adequate results.
What the Evidence Does Not Establish
The research does not support medical cannabis as a first-line treatment for PTSD or as a substitute for evidence-based treatments including trauma-focused CBT or EMDR. The Nacasch et al. study is a retrospective cohort of 14 patients without a control group. Sheehy et al.’s own data did not produce statistically significant associations between cannabis use characteristics and PTSD severity. The Lucas et al. survey is cross-sectional and self-reported. The St. Cyr et al. study describes prevalence and correlates, not clinical outcomes.
The defensible clinical position is that meaningful peer-reviewed evidence supports authorization for chronic pain and sleep disturbance in veteran patients, and for use as an adjunct where other approaches have been tried — and that the evidence base does not support first-line use or replacement of guidelines-based care for PTSD.
VAC Coverage and the Authorization Process
Veterans Affairs Canada reimburses authorized medical cannabis for eligible veterans through its non-insured health benefits program, administered by Medavie Blue Cross. Authorization requires a prescription from a qualified healthcare provider. RCMP members, Canadian Armed Forces personnel, and those covered under the Interim Federal Health Program have parallel coverage pathways. A licensed Canadian producer handles supply and billing directly — the clinician’s role is the authorization itself.
This article summarizes published peer-reviewed research for informational purposes. It is intended for healthcare professionals and does not constitute clinical guidelines. Clinicians should use their professional judgment in applying this evidence to individual patient care.
Yes. A 2023 study in BMC Psychiatry examined 415 CAF members and veterans attending a specialized mental health outpatient clinic and found that 45.1% reported current cannabis use for medical or recreational purposes, in the absence of clinical practice guidelines addressing it.
Authorization moves a veteran’s cannabis access from an unregulated source — unknown THC concentration, variable quality, no clinical record — to a licensed, quality-controlled supply with documented dosing, a medical record of use, and VAC reimbursement eligibility. For most veterans already using cannabis, authorization does not introduce new use; it changes the safety and consistency of access.
A 2023 retrospective study in Frontiers in Psychiatry followed 14 combat veterans with treatment-resistant PTSD and found significant improvements in sleep quality and PTSD severity following medical cannabis use. The treatment-resistant designation means these were patients for whom prior pharmacological and psychotherapy approaches had not produced adequate results. The study is a retrospective cohort of 14 patients without a control group, not a randomized controlled trial.
Yes. Prior studies cited in Sheehy et al. (2025) found a recurring pattern in which recreational cannabis use was associated with worse PTSD outcomes in some studies, and medicinal use with improved outcomes. Sheehy et al.’s own data did not reach statistical significance for this association, and the overall literature remains equivocal. For clinicians, the pattern points toward authorization as a harm reduction intervention for veterans already using cannabis recreationally — not just as a prescribing decision for cannabis-naive patients.
References
- Lucas, Baron & Jikomes (2019). Harm Reduction Journal, 16(1): 9. DOI: 10.1186/s12954-019-0278-6
- Nacasch, Avni & Toren (2023). Frontiers in Psychiatry, 13: 1014630. DOI: 10.3389/fpsyt.2022.1014630
- Sheehy, Storey, Rash, Tippin, Parihar & Harris (2025). Journal of Veterans Studies, 11(1): 30–46. DOI: 10.21061/jvs.v11i1.582
- St. Cyr, Nazarov, Le et al. (2023). BMC Psychiatry, 23: 836. DOI: 10.1186/s12888-023-05237-2
- Storey, Keeler-Villa, Harris, Anthonypillai, Tippin, Parihar & Rash (2023). Canadian Journal of Pain, 7(1): 2232838. DOI: 10.1080/24740527.2023.2232838